论文部分内容阅读
日前,日本厚生、劳动和福祉省批准了盐野义制药公司提交的培拉米韦注射剂(peramivir/Rapiacta)的新药申请,用于单剂静脉内输注300mg治疗成人非并发性季节性流感病毒感染及单剂或多剂(一日1次)静脉内输注600
Recently, the Ministry of Health, Welfare and Labor of Japan approved the new drug application of peramivir / Rapiacta submitted by Yanji Yike Pharmaceutical for the single-dose intravenous infusion of 300 mg of adult non-concurrent seasonal influenza virus Infections and single or multi-dose (once a day) Infusion 600